Table 1 Patient characteristics.

From: Relationship of the standard uptake value of 18F-FDG-PET-CT with tumor-infiltrating lymphocytes in breast tumors measuring ≥ 1 cm

 

Number (%)

Age (years), median (range)

53.2 (24–87)

Histology

 Invasive ductal carcinoma

174 (86.1)

 Invasive lobular carcinoma

17 (8.4)

 Others

11 (5.4)

T stage

 1

118 (58.4)

 2

80 (39.6)

 3

4 (2.0)

N stage

 0

148 (73.3)

 1

45 (22.3)

 2

7 (3.5)

 3

2 (1.0)

Histologic grade1

 I or II

156 (77.2)

 III

45 (22.3)

Nuclear grade1

 1 or 2

135 (66.3)

 3

65 (32.2)

ER positive

163 (80.7)

PR positive

137 (67.8)

HER2 positive2

42 (20.8)

Subtypes

 Luminal/HER2(−)

145 (71.8)

 HER2(+)

32 (15.8)

 TNBC

25 (12.4)

Ki-67 labeling index1

  < 14%

111 (55.2)

  ≥ 14%

90 (44.6)

AR (%), mean (SD)

87.01 (± 25.25)

SUV max, median (range)

4.68 (0.63–18.54)

TIL (%), median (range)

15 (5–95)

  1. ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor-2, TNBC triple-negative breast cancer, AR androgen receptor, SUV standard uptake value, TIL tumor-infiltrating lymphocytes.
  2. 1Missing value.
  3. 2HER2 positivity was defined as 3 + on immunohistochemistry or amplification on fluorescence in situ hybridization.
Back to article page